BACE1 and Alzheimer disease: However, clinical trials investigating BACE-1 inhibitors have faced challenges, including safety concerns and limited efficacy, underscoring the complexity of targeting this enzyme in AD (Bazzari and Bazzari, 2022; Munj and Patil, 2022; Vassar et al., 1999).